[Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver].
OBJECTIVE
To investigate the protective mechanism of dipyridamole preconditioning against hepatic ischemia/reperfusion injury.


METHODS
Thirty SD rats were randomly divided into normal control group, ischemia/reperfusion group, and dipyridamole group, with 10 rats in each group. Using 45-minute ischemia/reperfusion rat model at normal temperature, 10 mg/kg of dipyridamole normal saline were injected into portal vein before ischemia. Only normal saline was injected in the ischemia/reperfusion group. An hour later, blood was obtained from the portal vein to determine the enzyme levels, including alanine aminotransferase (ALT) , lactate dehydrogenase (LDH) and tumor necrosis factor-alpha (TNF-alpha), and endothelin-1 (ET-1). The alteration in pathological morphology of the ischemia lobe was observed. The content of adenosine phosphates in the liver was determined.


RESULTS
The ALT and LDH activity, TNF-alpha, ET-1 levels were significantly higher in the ischemia/reperfusion group than those in the control group (all P<0.01). The levels of these variables were much lower in the dipyridamole group than those of the ischemia/reperfusion group (P<0.01), but little higher than those of the control group (P>0.05). The adenosine phosphates levels of ischemia/reperfusion group were significantly lower than those of the control group (P<0.01). They were much higher in the dipyridamole group than those of the ischemia/reperfusion group (P<0.01), but little higher than those of the control group (P>0.05). The control group had obvious alteration in pathological morphology, but only slight alteration was found in dipyridamole group, compared with control group.


CONCLUSIONS
Dipyridamole preconditioning protects against ischemia/reperfusion injury of the liver.
Hong
Yong
Y
Department of Hepatobiliary Surgery, Nanxishan Hospital, Guilin Medical College, Guilin 541002, Guangxi, China. hongyong0001@126.com
Liao
Wen-sheng
WS
Mo
Rui-xiang
RX
D000818:Animals; D004176:Dipyridamole / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D019194:Ischemic Preconditioning; D008099:Liver / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
D004176:Dipyridamole